Affimed (NASDAQ:AFMD – Get Free Report) shares crossed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $4.90 and traded as low as $2.92. Affimed shares last traded at $3.00, with a volume of 43,843 shares.
Analyst Upgrades and Downgrades
AFMD has been the subject of several analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Affimed in a report on Monday, September 9th. HC Wainwright reissued a “buy” rating and issued a $10.00 price target on shares of Affimed in a research note on Friday, September 6th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Affimed has a consensus rating of “Moderate Buy” and an average target price of $20.00.
View Our Latest Stock Analysis on Affimed
Affimed Stock Performance
Affimed (NASDAQ:AFMD – Get Free Report) last released its earnings results on Thursday, September 5th. The biopharmaceutical company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($1.00) by ($0.09). The company had revenue of $0.17 million during the quarter, compared to analyst estimates of $1.67 million. Affimed had a negative net margin of 2,922.74% and a negative return on equity of 155.30%. Analysts expect that Affimed will post -4.25 earnings per share for the current fiscal year.
Institutional Trading of Affimed
A hedge fund recently bought a new stake in Affimed stock. Choreo LLC acquired a new position in shares of Affimed (NASDAQ:AFMD – Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 10,000 shares of the biopharmaceutical company’s stock, valued at approximately $54,000. Choreo LLC owned about 0.07% of Affimed as of its most recent SEC filing. Institutional investors own 30.82% of the company’s stock.
About Affimed
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia.
Further Reading
- Five stocks we like better than Affimed
- Where to Find Earnings Call Transcripts
- Why Fastenal Stock Could Hit New Highs After Strong Q3 Results
- What to Know About Investing in Penny Stocks
- Why Eli Lilly Stock Is Soaring—and How It Plans to Stay on Top
- High Flyers: 3 Natural Gas Stocks for March 2022
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.